echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pioglitazone Hydrochloride Tablets, a wholly-owned subsidiary of Kangen Bay, passed the consistency evaluation of generic drugs

    Pioglitazone Hydrochloride Tablets, a wholly-owned subsidiary of Kangen Bay, passed the consistency evaluation of generic drugs

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 20, Kang Enbei issued an announcement stating that its wholly-owned subsidiary Hangzhou Kang Enbei received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration, and pioglitazone hydrochloride tablets passed the consistency evaluation of generic drugs


    Pioglitazone hydrochloride tablets are mainly used to treat type 2 diabetes


    As of the disclosure date of this announcement, three manufacturers of pioglitazone hydrochloride tablets that have passed the consistency evaluation include Hangzhou Kangenbei, a wholly-owned subsidiary of the company


    Meinenet data shows that in 2020, the sales of pioglitazone hydrochloride oral preparations in public medical institutions and retail pharmacies are 774 million yuan and 123 million yuan, respectively.


    Up to now, Hangzhou Conba has invested approximately RMB 10.


    According to relevant national policies, medicines that pass the consistency evaluation will receive greater support in areas such as medical insurance payment and procurement by medical institutions


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.